Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05233033 · ClinicalTrials.gov registry record · Phase 1

Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL

A Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, sponsored by Kymera Therapeutics.

Completed
Registry status
Phase 1
Development phase
7
Enrollment target
8
Study locations

NCT05233033 is a Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma that has completed, run by Kymera Therapeutics. The registered enrollment target is 7 participants, below the 219-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (97% lower). The trial reports 8 study locations across 7 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05233033, a Phase 1 study of Diffuse Large B Cell Lymphoma and Non-Hodgkin Lymphoma, has completed, sponsored by Kymera Therapeutics.

COMPLETED
Registry status
Phase 1
Development phase
7 participants
Enrollment target
8
Study locations

Study Summary

This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL. The Phase 1a stage of the study will explore escalating doses of single-agent KT-413. The Phase 1b stage will be split into 2 expansion cohorts to further characterize the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in MYD88 mutant and MYD88 wild-type R/R DLBCL.

Conditions Studied

Diffuse Large B Cell Lymphoma Non-Hodgkin Lymphoma DLBCL MYD88 Gene Mutation

Interventions

  • DRUG KT-413

Study Locations (8)

Other

  • University College London Hospitals - London
  • University Hospital Southampton NHS Foundation Trust - Southampton

District of Columbia

  • MedStar Georgetown University Hospital - Washington D.C.

Kentucky

  • Norton Cancer Institute - Louisville

Michigan

  • Henry Ford Health System - Detroit

New York

  • Memorial Sloan Kettering Cancer Center - New York

Texas

  • MD Anderson Cancer Center - Houston

Virginia

  • University of Virginia Comprehensive Cancer Center - Charlottesville

Trial Details

FieldValue
Enrollment Target 7 participants
Start Date 2022-06-13
Est. Completion 2023-07-28
Phase Phase 1

Sponsor

Kymera Therapeutics

10 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05233033

The ClinicalTrials.gov registry entry for NCT05233033 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 219-participant average among 114 other Diffuse Large B Cell Lymphoma trials with a reported enrollment target (97% lower). The listed sponsor is Kymera Therapeutics, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Diffuse Large B Cell Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which KT-413 is the first listed.

NCT05233033 reports 8 study locations spanning 7 distinct geographic areas - top geographies include Other, District of Columbia, Kentucky.

Frequently Asked Questions

What is clinical trial NCT05233033 about?

NCT05233033 is a clinical study titled "Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL". This Phase 1a/1b study will evaluate the safety, tolerability and the pharmacokinetics/ pharmacodynamics (PK/ PD) of KT-413 in patients with R/R NHL. The Phase 1a stage of the study will explore escalating doses of single-agent KT-413. The Phase 1b stage will be split into 2 expansion cohorts to fur...

What is the current status of trial NCT05233033?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 7 participants. The study started on 2022-06-13. Estimated completion is 2023-07-28.

What conditions does trial NCT05233033 study?

This clinical trial studies the following conditions: Diffuse Large B Cell Lymphoma, Non-Hodgkin Lymphoma, DLBCL, MYD88 Gene Mutation.

What interventions are being tested in trial NCT05233033?

The interventions under investigation include: KT-413 (DRUG).

Who is sponsoring clinical trial NCT05233033?

This trial is sponsored by Kymera Therapeutics, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05233033 being conducted?

This trial has 8 study locations across District of Columbia, Kentucky, Michigan, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Diffuse Large B Cell Lymphoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Diffuse Large B Cell Lymphoma

All registered trials for this condition

Non-Hodgkin Lymphoma

All registered trials for this condition

District of Columbia

All trials with a study site in District of Columbia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.